Heterogeneous cell response to topotecan in a CFSE-based proliferation test

Cytometry Part A

Volumn 62, Issue 2, 2004, Pages 118-128

  Matera, Giada ^a   Lupi, Monica ^a   Ubezio, Paolo ^a,b  

^a Biophysics Unit   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Carboxyfluorescein diacetate succinimidyl ester; Cell division; Cell proliferation; Complexity; Drug effects; Flow cytometry; Mathematical models; Topotecan

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; TOPOTECAN;

ALGORITHM; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL HETEROGENEITY; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CLUSTER ANALYSIS; CONTROLLED STUDY; COULTER COUNTER; DATA ANALYSIS; DRUG RESPONSE; DRUG TRANSPORT; FLOW CYTOMETRY; FLUORESCENCE; HISTOGRAM; HUMAN; HUMAN CELL; MATHEMATICAL ANALYSIS; NORMAL DISTRIBUTION; OUTCOMES RESEARCH; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; EVALUATION STUDIES; FEMALE; FLOW CYTOMETRY; FLUORESCEINS; FLUORESCENT DYES; FLUOROMETRY; HUMANS; OVARIAN NEOPLASMS; SUCCINIMIDES; TIME FACTORS; TOPOTECAN;

EID: 9644268056     PISSN: 15524922     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.a.20097     Document Type: Article

References (24)

1. Weston SA, Parish CR. New fluorescent dyes for lymphocyte migration studies. Analysis by flow cytometry and fluorescence microscopy. J Immunol Methods 1990;133:87-97.
2. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994;171:131-137.
3. Schmid I, Schmid P, Giorgi JV. Conversion of logarithmic channel numbers into relative linear fluoresence intensity. Cytometry 1988;9:533-588.
4. Parks DR, Bigos M, Moore WA. Logarithmic amplifier transfer function evaluation and procedures for logamp optimization and data correction [abstract 155]. Cytometry 1988;9:27.
5. Plate J, Petersen KS, Buckingham L, Shahidi H, Schofield CM. Gene expression in chronic lymphocytic leukemia B cells and changes during induction of apoptosis. Exp Hematol 2000;28:1214-1224.
6. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignabt progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002;99:3792-3800.
7. Lyons AB, Hasbold J, Hodgkin PD. Flow cytometric analysis of cell division history using dilution of carboxyfluorescein diacetate succinimidyl ester, a stably integrated fluorescent probe. Methods Cell Biol 2003;63:375-398.
8. Khil LY, Kim JY, Yoon JB, Kim JM, Yoon Y, Yoon MY, Moon CK, Lee JH, Ha J, Kim SS, Kang I. Insulin has a limited effect on cell cycle progression in 3T3 L1 fibroblasts. Mol Cells 1997;7:742-8.
9. Nordon RE, Nakamura M, Ramirez C, and Odell R. Analysis of growth kinetics by division tracking. Immunol Cell Biol 1999;77:523-529.
10. Hasbold J, Gett AV, Rush JS, Deenick E, Avery D, Jun J, Hodgkin PD. Quantitative analysis of lymphocyte differentiation and proliferation in vitro using carboxyfluorescein succinimidyl ester. Immunol Cell Biol 1999;77:516:522.
11. Demitriu IE, Mohor W, Kolowos W, Kern P, Kalden JR, Hermann M. 5,6-Carboxyfluorescein diacetate succinimidyl ester-labeled apoptotic and necrotic as well as detergent-treated cells can be traced in composite cell samples. Anal Biochem 2001;299:247-252.
12. Fazekas de St Groth B, Smith AL, Koh WP, Girgis L, Cook MC, Bertolino P. Carboxyfluorescein diacetate succinimidyl ester and the virgin lymphocyte: a marriage made in heaven. Immunol Cell Biol 1999;77:530-538.
13. Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer the role of topotecan in second-line chemotherapy. Oncologist 1994;4:87-94.
14. Ormrod D, Spencer CM. Topotecan: a review of its efficacy in small cell lung cancer. Drugs 1999;58:533-551.
15. McDonald AC, Brown R. Induction of p53-dependent and p53-independent cellular responses by topoisomerase I inhibitors. Br J Cancer 1998;78:745-751.
16. Taron M, Plasencia C, Abad A, Martin C, Guillot M. Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumour-derived cell lines. Invest New Drugs 2000;18:139-147.
17. Feeney GP, Errington RJ, Wiltshire M, Marquez N, Chappell SC, Smith PJ. Tracking the cell cycle origins for escape from topotecan action by breast cancer cells. Br J Cancer 2003;88:1310-1317.
18. Lupi M, Matera G, Branduardi D, D'Incalci M, Ubezio P. Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approach. Cancer Res 2004;64:2825-2832.
19. Sena G, Onado C, Cappella P, Montalenti F, Ubezio P. Measuring the complexity of cell cycle arrest and killing of drugs: kinetics of phase-specific effects induced by Taxol. Cytometry 1999;37:113-124.
20. Montalenti F, Sena G, Cappella P, Ubezio P. Simulating cancer-cell kinetics after drug treatment: application to cisplatin on ovarian carcinoma. Phys Rev E Stat Nonlin Soft Matter Phys 1998;57:5877-5887.
21. Wells AD, Gudmundsdottir H, Turka LA. Following the fate of individual T cells throughout activation and clonal expansion. J Clin Invest 1997;100:3173-3783.
22. Givan AL, Fisher JL, Waugh M, Ernstoff MS, Wallace PK. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods 1999;230:99-112 [erratum J Immunol Methods 1999;237:207].
23. Givan AL, Fisher JL, Waugh M, Ernstoff MS, Wallace PK. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods 1999;230:99-112 [erratum J Immunol Methods 1999;237:207].
24. Song HK, Noorchasham H, Lieu YK, Rostami S, Greeley SA, Barker CF, Naji A. Cutting edge: alloimmune responses against major and minor histocompatibility antigens. Distinct division kinetics and requirement for CD28 costimulation. J Immunol 1999;162:2467-2471.